Therapy-Related Acute Nonlymphocytic Leukemia with Monocytic Features and Rearrangement of Chromosome 11q
Authors: Russell DeVore
Journal: Annals of Internal Medicine (1989)

Brief Reports1 May 1989Therapy-Related Acute Nonlymphocytic Leukemia with Monocytic Features and Rearrangement of Chromosome 11qRussell DeVore, MD, James Whitlock, MD, John D. Hainsworth, MD, David H. Johnson, MDRussell DeVore, MD, James Whitlock, MD, John D. Hainsworth, MD, David H. Johnson, MDAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-110-9-740 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptAcute nonlymphocytic leukemia has been increasingly recognized as a complication of cancer treatment. Therapy-related leukemia has commonly been reported (1) after treatment of lymphomas and solid tumors in which alkylating agents (in particular cyclophosphamide, chlorambucil, and melphalan) have been a major component of the patient's initial therapy. Newer agents such as cisplatin and etoposide are not commonly recognized as being leukemogenic. In one large cohort of patients with testicular cancer, no case of therapy-related leukemia was identified (2) although all patients received cisplatin-based chemotherapy. Therefore, when one of our patients with testicular cancer developed acute nonlymphocytic leukemia after chemotherapy with...References1. Koeffler H. Syndromes of acute non-lymphocytic leukemia. Ann Intern Med. 1987;107:748-58. LinkGoogle Scholar2. RothGreistKubilisWilliamsEinhorn BAPSL. Cisplatin-based combination chemotherapy for disseminated germ cell tumors: long-term follow-up. J Clin Oncol. 1988;6:1239-47. CrossrefMedlineGoogle Scholar3. RetainKaminerBitran MLJ. Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung. Blood. 1987;70:1412-7. CrossrefMedlineGoogle Scholar4. DewaldMorrison-DeLapSchuchardSpurbeckPierre GSKJR. A possible specific chormosome marker for monocytic leukemia: three more patients with t(9;11) (p22;q24) and another with t(11;17) (q24;q21), each with acute monoblastic leukemia. Cancer Genet Cytogenet. 1983;8:203-12. CrossrefMedlineGoogle Scholar5. WehKabischLandbeckHossfeld HHGD. Translocation (9;11) (p21;q23) in a child with acute monoblastic leukemia following 2½ years after successful chemotherapy for neuroblastoma. J Clin Oncol. 1986;4:1518-20. CrossrefMedlineGoogle Scholar6. FenauxJouetBautersLaiLepelley PJFJP. Translocation t(9;11) (p21;q23) with acute myelomonocytic leukemia after chemotherapy for osteosarcoma: good response to antileukemic drugs [Letter]. J Clin Oncol. 1987;5:1304. CrossrefMedlineGoogle Scholar7. JohnsonPorterListHandeHainsworthGreco DLAKJF. Acute nonlymphocytic leukemia after treatment of small cell lung cancer. Am J Med. 1986;81:962-8. CrossrefMedlineGoogle Scholar8. ChakSikicTuckerHornsCox LBMRR. Increase incidence of acute nonlymphocytic leukemia following therapy in patients with small cell carcinoma of the lung. J Clin Oncol. 1984;2:385-90. CrossrefMedlineGoogle Scholar9. Pedersen-BjergardOsterlindHansenPhilipPedersenHansen JKMPAH. Acute nonlymphocytic leukemia, preleukemia, and solid tumors following intensive chemotherapy of small cell carcinoma of the lung. Blood. 1985;66:1393-7. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: From Vanderbilt University, Nashville, Tennessee. For current author addresses, see end of text. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byCoupling the core of the anticancer drug etoposide to an oligonucleotide induces topoisomerase II-mediated cleavage at specific DNA sequencesEtoposide Quinone Is a Covalent Poison of Human Topoisomerase IIβChromosomal effects of non-alkylating drug exposure in oncology personnelTopoisomerase II and leukemiaEtoposide Catechol Is an Oxidizable Topoisomerase II PoisonTherapy-Related Acute Myelogenous LeukemiaRearrangement of the Myeloid/Lymphoid Leukemia Gene in Therapy-Related Myelodysplastic Syndrome in Patients Previously Treated with Agents Targeting DNA Topoisomerase IIInteractions between the Etoposide Derivative F14512 and Human Type II Topoisomerases: Implications for the C4 Spermine Moiety in Promoting Enzyme-Mediated DNA CleavageAcute Myeloid LeukemiaDNA topoisomerase II, genotoxicity, and cancerTopoisomerase II and the etiology of chromosomal translocationsChronic myelomonocytic leukaemia after platinum-based therapy for non-small cell lung cancer: case report and review of the literatureAcute Monocytic Leukemia (French-American-British classification M5) Does Not Have a Worse Prognosis Than Other Subtypes of Acute Myeloid Leukemia: A Report From the Eastern Cooperative Oncology GroupEvaluation for the Development of 11q23 Rearrangements in Lymphoma Patients Treated with a High Dose VP-16 and Cyclophosphamide Salvage RegimenTherapy-induced leukemias and myelodysplastic syndromes after breast cancer treatment: An underemphasized clinical problemGenetic pathways in therapy-related myelodysplasia and acute myeloid leukemiaLeukemias related to treatment with DNA topoisomerase II inhibitorsThe amino terminus targets the mixed lineage leukemia (MLL) protein to the nucleolus, nuclear matrix and mitotic chromosomal scaffoldsTOPOISOMERASE II INHIBITOR-RELATED ACUTE MYELOID LEUKAEMIAMorphology and Classification of Acute Myeloid LeukemiasTumorigenesis in mice with a fusion of the leukaemia oncogene Mll and the bacterial lacZ geneAcute myelogenous leukemia after exposure to strontium-89 for the treatment of adenocarcinoma of the prostateTopoisomerase II as a target for anticancer drugs: When enzymes stop being niceCytogenetic and myelodysplastic alterations after autologous hemopoietic stem cell transplantationRisk of Second Malignancies Following Treatment for Genitourinary TumorsMechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzymeSecondary leukemias induced by topoisomerase-targeted drugsApurinic Sites Are Position-specific Topoisomerase II PoisonsTHERAPY-RELATED MYELOID LEUKEMIAMLL fusion genes in the 11q23 acute leukemiasSpontaneous regression of chemotherapy-refractory non-hodgkin's lymphoma preceding the development of secondary leukaemiaCALLA positive acute lymphoblastic leukemia after etoposide-based therapy for Ewing's sarcomaAbasic Sites Stimulate Double-stranded DNA Cleavage Mediated by Topoisomerase IIDetection of major and minor bcr/abl fusion gene transcripts in a patient with acute undifferentiated leukemia secondary to treatment with an alkylating agentEtoposide: Twenty years laterMutagenicity and carcinogenicity of topoisomerase-interactive agentsProlonged administration of low dose infusional etoposide in patients with advanced malignancies. A phase I/II studySite-specific cleavage of a DNA hairpin by topoisomerase II. DNA secondary structure as a determinant of enzyme recognition/cleavage.Therapy-related acute myeloid leukemia following treatment with epipodophyllotoxins: Estimating the risksAcute myeloid leukemia in patients treated for rhabdomyosarcoma with cyclophosphamide and low-dose etoposide on intergroup rhabdomyosarcoma study III: An interim reportLCH-I: A randomized trial of etoposide vs. vinblastine in disseminated langerhans cell histiocytosisTherapy-Related Acute Promyelocytic Leukemia: A Report on 16 CasesDefining functional drug-interaction domains on topoisomerase II by exploiting mechanistic differences between drug classesPharmacodynamics and long-term toxicity of etoposideAcute promyelocytic leukemia witht(15;17) abnormality after chemotherapy containing etoposide for langerhans cell histiocytosisEtoposide and secondary haematological malignancies: Coincidence or causality?Late effects of childhood cancer therapy“Etoposide in the treatment of six children with langerhans cell histiocytosis (histiocytosis X)” by Viana et al.Cell proliferation and differentiation in chemical leukemogenesisA Comparative Analysis of Alkylating Agent and Epipodophyllotoxin-Related LeukemiasTherapy-Related Acute Myelogenous Leukemia Associated with 11q23 Chromosomal Abnormalities and Topoisomerase II Inhibitors: Report of Four Additional Cases and Brief CommentaryIncidence of secondary acute myelogenous leukemia after treatment of childhood acute lymphoblastic leukemiaCytogenetic and molecular analysis of chromosome 11q23 abnormalities in leukaemiaSecondary acute lymphoblastic leukemia with t (4; 11): Report on two cases and review of the literatureIntrinsic intermolecular DNA ligation activity of eukaryotic topoisomerase II. Potential roles in recombination.Epipodophyllotoxins, alkylating agents, and radiation and risk of secondary leukaemia after childhood cancer.Therapy-related acute myeloid leukemia secondary to inhibitors of topoisomerase II: From the bedside to the target genesCytogenetic Abnormalities in Childhood Acute Lymphoblastic Leukemia Correlates with Clinical Features and Treatment OutcomeAcute Myeloid Leukemia in Children Treated with Epipodophyllotoxins for Acute Lymphoblastic LeukemiaEpipodophyllotoxin-related leukemia. Identification of a new subset of secondary leukemiaMalignant Hematologic Disorders Arising from Mediastinal Germ Cell Tumors. A Review of Clinical and Biologic FeaturesTherapy Related Myelodysplastic Syndrome and Leukemia with no “Unfavourable” Cytogenetic Findings have a Good Response to Intensive Chemotherapy: A Report on 15 CasesTherapy-related myeloid leukaemiaUncoupling the DNA cleavage and religation activities of topoisomerase II with a single-stranded nucleic acid substrate: evidence for an active enzyme-cleaved DNA intermediateHematologic Neoplasia Associated with Primary Mediastinal Germ-Cell TumorsImplication of prior treatment with drug combinations including inhibitors of topoisomerase II in therapy-related monocytic leukemia with a 9;11 translocation 1 May 1989Volume 110, Issue 9Page: 740-742KeywordsAcute myeloid leukemiaCancer treatmentChemotherapyChromosomesCyclophosphamideLymphocytic leukemiaLymphomaPatientsTesticular cancer ePublished: 1 December 2008 Issue Published: 1 May 1989 PDF downloadLoading ...